Inclusion criteria:
* Caucasian female volunteers aged 35 to 65 years at the time of signing the Informed Consent Form (ICF).
* Signed Informed Consent Form (ICF).
* Fitzpatrick skin phototypes I-IV.
* Presence of visible signs of skin ageing.
* Presence of visible facial telangiectasias, primarily on the cheeks.
* Presence of facial erythema with a baseline score ≤ 3 on the 5-point Clinical Erythema Assessment (CEA) scale.
* Stable erythema-prone facial skin for at least 3 months prior to study inclusion, without clinical signs of active rosacea.
* In good general health, as determined by medical history.
* Body Mass Index (BMI) \< 35.
* Willingness and ability to:
* Comply with all study procedures and complete a subject diary.
* Maintain usual lifestyle habits throughout the study.
* Not initiate or modify oestrogen or progesterone therapies during the study.
* Maintain the same cosmetic and skincare routine and comply with sun protection guidelines throughout the study.
* Avoid rejuvenation treatments during the study.
* Refrain from consuming food supplements containing collagen or other protein-based supplements, methylsulfonylmethane (MSM), or anti-inflammatory and/or antioxidant compounds with a known or potential impact on skin inflammation or vascular response for the duration of the study.
Exclusion criteria:
* Pregnancy or breastfeeding.
* Vegan diet.
* Heavy smoking or frequent alcohol-induced flushing.
* Occupational or hobby-related excessive heat exposure (e.g. chefs, sauna workers) likely to interfere with vascular stability.
* Anticipated sunbathing or solarium use, or major planned changes in sun exposure before or during the study.
* Planned major changes during the study in:
* Skincare routine
* Hormonal therapy (contraception or hormone replacement therapy)
* Significant changes in dietary habits or dietary supplementation within 3 months prior to inclusion.
* Regular use within 3 months prior to inclusion of food supplements containing:
* Methylsulfonylmethane (MSM);
* Collagen or other protein-based supplements;
* Anti-inflammatory supplements (e.g. bioflavonoids/rutin, curcumin, EPA) and/or antioxidant supplements with a known or potential impact on skin inflammation or vascular response.
* Any diagnosed, uncontrolled, untreated, or unstable medical condition.
* Clinically significant history of metabolic, gastrointestinal, hepatic, renal, or haematological disease.
* Mental incapacity or psychiatric condition that may impair understanding of the study or compliance with study requirements.
* Any clinically significant acute or chronic inflammatory skin disease, including but not limited to acne, perioral dermatitis, psoriasis, atopic dermatitis, or lupus.
* Skin pigmentation disorders at the assessment sites.
* Active rosacea within 3 months prior to study entry, defined as the presence of papules/pustules, frequent flushing episodes typical of rosacea, or ocular involvement.
* Frequent vasomotor hot flushes (e.g. perimenopausal or menopausal), which may interfere with erythema assessments.
* Use of medications affecting skin or vascular reactivity, including but not limited to: systemic corticosteroids, anticoagulants (e.g. coumarins, heparin), vasodilators (e.g. hydralazine, nitroglycerin), antibiotics with potential to affect erythema or vascular response, immunomodulators, regular or long-term use of non-steroidal anti-inflammatory drugs (NSAIDs)
* Use of systemic retinoids within 3 months prior to study entry.
* Changes of skin care routine regimen within 4 weeks prior to study entry.
* Use of highly concentrated topical products (\>15% azelaic acid, 10% vitamin C…) affecting inflammatory or vascular facial responses within 4 weeks prior to study entry.
* Invasive rejuvenation treatments (e.g. medium or deep chemical peels, ablative or vascular laser therapies) within 6 months prior to study entry.
* Non-invasive or minimally invasive rejuvenation treatments (e.g. microneedling, mesotherapy, superficial chemical peels, radiofrequency, electrotherapy, ultrasound, IPL) within 3 months prior to study entry.
* Known or suspected allergy to any ingredient of the investigational product(s).
